61‐year‐old male, JAK2‐positive symptomatic PMFRuxolitinib monotherapyAnaemiaNavtemadlin via BOREAS (NCT03662126)Poor responseLiver involvement of myelofibrosisRuxolitinib and hydroxycarbamideDecrease in symptoms and spleen sizeTransfusion‐dependent anaemiaFedratinib via FREEDOM‐2 (NCT03952039)Improvement in symptoms, splenomegaly and transfusion‐dependence. The gene discussed is JAK2; the disease is Splenomegaly.